SCHEMBL6903135

SCHEMBL6903135

O=C1CCC2CCCCC12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
MAPT P10636 4/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 4/20 0.36
ALDH1A1 P00352 5/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NOS3 P29474 3/20 0.33
NOS1 P29475 3/20 0.33
NOS2 P35228 3/20 0.33
MT-CO2 P00403 2/20 0.33
ALOX5 P09917 2/20 0.33
TSHR P16473 1/20 0.33
MEN1 O00255 1/20 0.33
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7703871 1.00 CA1 (0.37) CA1CA2CA4MAPTHPGD
SCHEMBL7703873 1.00 CA1 (0.37) CA1CA2CA4MAPTHPGD
SCHEMBL7706418 0.97 KMT2A (0.39) CA1CA2CA4MAPTHPGD
SCHEMBL1626353 0.95
SCHEMBL16691801 0.95
SCHEMBL12333841 0.90 CA1 (0.42) CA1CA2CA4MAPTHPGD
SCHEMBL120444 0.90 CA1 (0.42) CA1CA2CA4MAPTHPGD
SCHEMBL22397285 0.90 CA1 (0.42) CA1CA2CA4MAPTHPGD
SCHEMBL11955 0.90 CA1 (0.42) CA1CA2CA4MAPTHPGD
SCHEMBL895510 0.90 CA1 (0.42) CA1CA2CA4MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0354920-A1 AMINO-9,10-SECOSTEROIDS THE UPJOHN COMPANY (US) 1990-02-21 EP claimed
WO-1988007527-A1 AMINO-9,10-SECOSTEROIDS THE UPJOHN COMPANY (US) 1988-10-06 WO claimed
WO-2023141593-A2 PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS THE SCRIPPS RESEARCH INSTITUTE (US) 2023-07-27 WO disclosed
CN-109722455-A Method, engineering bacteria and the application of microbial fermentation production paddy lactone 中国科学院天津工业生物技术研究所 2019-05-07 CN disclosed
CN-105622422-B A kind of bromo hexahydro indanone compounds and its production and use 南开大学 2017-12-05 CN disclosed
CN-105622422-B A kind of bromo hexahydro indanone compounds and its production and use 南开大学 2017-12-05 CN disclosed
WO-2017129113-A1 BROMOHEXAHYDROINDANONE COMPOUNDS, PREPARATION METHOD FOR SAME, AND USES THEREOF 南开大学 2017-08-03 WO disclosed
US-9518076-B2 Apparatus and process for preparing reactive lignin with high yield from plant biomass for production of fuels and chemicals WASHINGTON STATE UNIVERSITY (US) 2016-12-13 US disclosed
US-9268226-B2 Resin, resist composition and method for producing resist pattern SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-02-23 US disclosed
US-20150099868-A1 APPARATUS AND PROCESS FOR PREPARING REACTIVE LIGNIN WITH HIGH YIELD FROM PLANT BIOMASS FOR PRODUCTION OF FUELS AND CHEMICALS WASHINGTON STATE UNIVERSITY (US) 2015-04-09 US disclosed
US-8859182-B2 Resist composition and method for producing resist pattern SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-10-14 US disclosed
WO-2002087584-A1 COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS PFIZER PRODUCTS INC. (US) 2002-11-07 WO disclosed
EP-0921125-B1 1,3,8-Triazaspiro[4,5]decan-4-on derivatives HOFFMANN LA ROCHE (CH) 2002-01-30 EP disclosed
US-6043366-A USEFUL IN TREATING DISORDERS INVOLVING THE ORPHANIN FQ(A SEVENTEEN AMINO ACID LONG PEPTIDE) RECEPTOR. HOFFMAN-LA ROCHE INC. (US) 2000-03-28 US disclosed
EP-0921125-A1 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-06-09 EP disclosed
EP-0480871-B1 Synergistic agents and method for selective control of weeds CIBA GEIGY AG (CH) 1995-12-13 EP disclosed
WO-1993004070-A1 SUBSTITUTED ACRYLAMIDO-PENICILLANIC ACID DERIVATIVES SMITHKLINE BEECHAM, PLC (GB) 1993-03-04 WO disclosed
EP-0421752-A2 Substituted acrylamido-penicillanic acid derivatives Beecham Group p.l.c. (GB) 1991-04-10 EP disclosed
US-4784953-A NOCARDIA WHICH FORMS 4(3-PROPIONIC ACID-5-HYDROXY-7-METHYL INDANONE HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1988-11-15 US disclosed
US-3948903-A Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins PARKE, DAVIS & COMPANY (US) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099868-A1 APPARATUS AND PROCESS FOR PREPARING REACTIVE LIGNIN WITH HIGH YIELD FROM PLANT BIOMASS FOR PRODUCTION OF FUELS AND CHEMICALS HAAO, HAO2, HAO1 CA1 4219/4885CA2 3990/4885CA4 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.